Source: Cancer Research. Conference titles: San Antonio Breast Cancer Virtual Symposium. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, NEOPLASIAS MAMÁRIAS, MENOPAUSA, SISTEMA ÚNICO DE SAÚDE
ABNT
PIMENTEL, Franklin Fernandes et al. Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system. Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS20-PS9-27. Acesso em: 22 ago. 2024. , 2021APA
Pimentel, F. F., Buzatto, I. P. C., Rodrigues, T. C. G. F., Borba, J. M. C., Peruchi, K. P. I., Andrade, J. M. de, & Tiezzi, D. G. (2021). Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system. Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS20-PS9-27NLM
Pimentel FF, Buzatto IPC, Rodrigues TCGF, Borba JMC, Peruchi KPI, Andrade JM de, Tiezzi DG. Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system [Internet]. Cancer Research. 2021 ; 81( 4):[citado 2024 ago. 22 ] Available from: https://doi.org/10.1158/1538-7445.SABCS20-PS9-27Vancouver
Pimentel FF, Buzatto IPC, Rodrigues TCGF, Borba JMC, Peruchi KPI, Andrade JM de, Tiezzi DG. Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system [Internet]. Cancer Research. 2021 ; 81( 4):[citado 2024 ago. 22 ] Available from: https://doi.org/10.1158/1538-7445.SABCS20-PS9-27